Literature DB >> 20486202

Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study.

Wei-Wen Su1, King-Teh Lee, Yao-Tsung Yeh, Maw-Soan Soon, Chao-Ling Wang, Ming-Lung Yu, Shen-Nien Wang.   

Abstract

Deregulation of insulin-like growth factor-1 (IGF-1) has been implicated in the pathogenesis of several malignancies. This study aimed to investigate the association of changes in circulating IGF-1 with hepatocellular carcinoma (HCC). The radioimmunoassay was used to analyze serum IGF-1 levels of 65 HCC patients and 165 healthy subjects. Serum IGF-1 levels were significantly decreased in the HCC patients as compared with the healthy subjects (158.46+/-105.07 vs. 247.63+/-149.96 ng/mL, P<0.001). Furthermore, insulin resistance was significantly higher in the HCC patients than the healthy subjects (P=0.027). In addition, the significant correlations of serum IGF-1 levels with age and insulin resistance in the healthy subjects were not noted in the HCC patients. Intriguingly, individuals with hepatitis C virus (HCV), not hepatitis B virus, had remarkably decreased IGF-1 levels in both groups of the HCC patients and healthy subjects. Moreover, in the HCV subgroup, serum IGF-1 levels were significantly reduced in the HCC patients than the healthy subjects (113.14+/-71.28 vs. 172.42+/-74.02 ng/mL, P=0.003). In conclusion, decreased serum IGF-1 levels were associated with HCC and the decrease was remarkably noted in those patients concomitant with chronic hepatitis C. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486202      PMCID: PMC6647566          DOI: 10.1002/jcla.20320

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  39 in total

Review 1.  The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function.

Authors:  Corinna Bähr; Bernd Groner
Journal:  Growth Factors       Date:  2005-03       Impact factor: 2.511

2.  Normal growth and development in the absence of hepatic insulin-like growth factor I.

Authors:  S Yakar; J L Liu; B Stannard; A Butler; D Accili; B Sauer; D LeRoith
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

3.  Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.

Authors:  R Kaaks; P Toniolo; A Akhmedkhanov; A Lukanova; C Biessy; H Dechaud; S Rinaldi; A Zeleniuch-Jacquotte; R E Shore; E Riboli
Journal:  J Natl Cancer Inst       Date:  2000-10-04       Impact factor: 13.506

Review 4.  Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1.

Authors:  Derek LeRoith; Shoshana Yakar
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2007-03

Review 5.  Oncogenesis and transforming viruses: the hepatitis B virus and hepatocellularcarcinoma--the etiopathogenic link.

Authors:  Alvin T C Lee; Caroline G L Lee
Journal:  Front Biosci       Date:  2007-01-01

Review 6.  New concepts: growth hormone, insulin-like growth factor-I and the kidney.

Authors:  Ralph Rabkin; Franz Schaefer
Journal:  Growth Horm IGF Res       Date:  2004-08       Impact factor: 2.372

Review 7.  The insulin-like growth factor system in multiple sclerosis.

Authors:  Daniel Chesik; Nadine Wilczak; Jacques De Keyser
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

Review 8.  Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.

Authors:  David R Clemmons
Journal:  Nat Rev Drug Discov       Date:  2007-10       Impact factor: 84.694

9.  Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis.

Authors:  T Vyzantiadis; S Theodoridou; O Giouleme; P Harsoulis; N Evgenidis; A Vyzantiadis
Journal:  Hepatogastroenterology       Date:  2003 May-Jun

10.  Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease.

Authors:  A Donaghy; R Ross; A Gimson; S C Hughes; J Holly; R Williams
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

View more
  26 in total

Review 1.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

2.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

3.  I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Authors:  Ahmed O Kaseb; James L Abbruzzese; Jean-Nicolas Vauthey; Thomas A Aloia; Eddie K Abdalla; Manal M Hassan; E Lin; Lianchun Xiao; Adel S El-Deeb; Asif Rashid; Jeffrey S Morris
Journal:  Oncology       Date:  2011-08-03       Impact factor: 2.935

4.  Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization.

Authors:  Sheng Liu; Yanhua Liu; Xuewen Jiang
Journal:  Exp Ther Med       Date:  2015-12-16       Impact factor: 2.447

5.  Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis.

Authors:  Hamid Ceylan
Journal:  Med Oncol       Date:  2021-04-26       Impact factor: 3.064

Review 6.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

7.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

8.  Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Authors:  Reham Abdel-Wahab; Manal M Hassan; Bhawana George; Roberto Carmagnani Pestana; Lianchun Xiao; Sahin Lacin; Suayib Yalcin; Ahmed S Shalaby; Humaid O Al-Shamsi; Kanwal Raghav; Robert A Wolff; James C Yao; Lauren Girard; Abedul Haque; Dan G Duda; Simona Dima; Irinel Popescu; Hesham A Elghazaly; Jean-Nicolas Vauthey; Thomas A Aloia; Ching-Wei Tzeng; Yun Shin Chun; Asif Rashid; Jeffrey S Morris; Hesham M Amin; Ahmed O Kaseb
Journal:  Oncology       Date:  2020-10-07       Impact factor: 2.935

9.  Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma.

Authors:  S Karabulut; D Duranyıldız; F Tas; U Gezer; F Akyüz; M Serilmez; E Ozgür; C T Yasasever; S Vatansever; N F Aykan
Journal:  Tumour Biol       Date:  2013-11-23

10.  Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C.

Authors:  Agnieszka Adamek; Aldona Kasprzak; Agnieszka Seraszek; Hanna Mikoś; Aleksandra Bura; Iwona Mozer-Lisewska
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.